developed to evaluate the relative effectiveness between the NOACs and warfarin for the primary efficacy endpoint of stroke or systemic embolism (SE) and primary safety endpoint of major hemorrhage. Secondary endpoints included ischemic stroke, hemorrhagic stroke, SE, myocardial infarction, intracranial hemorrhage, gastrointestinal hemorrhage, cardiovascular-related mortality, and all-cause mortality. A probability of best treatment was calculated for each antithrombotic agent for the different outcomes. RESULTS: Dabigatran-150mg, rivaroxaban, and apixaban showed significant relative risk (RR) reductions over warfarin for stroke or SE (RRϭ0.65, 0.78, 0.79, respectively). However, indirect comparisons did not reveal significant differences between the individual NOACs. For the primary safety endpoint, dabigatran-110mg was significantly better than warfarin (RRϭ0.81) and rivaroxaban (RRϭ0.79) whereas apixaban showed significant reduction over warfarin, and rivaroxaban (RRϭ0.70, 0.75, 0.69, respectively). Significant differences between the NOACs were also found for secondary endpoints of hemorrhagic stroke, intracranial hemorrhage, and gastrointestinal hemorrhage. However, no significant findings were observed for cardiovascular and all-cause mortality. CONCLUSIONS: Overall, the NOACs showed varying levels and areas of improvement over warfarin. The analyses identified dabigatran-150mg and apixaban as the best option for the prevention of stroke or SE and major hemorrhage, respectively. 
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PCV12 EFFICACY OF HEART FAILURE PHARMACOLOGICAL TREATMENT CLASSES AND COMBINATIONS: NETWORK META-ANALYSES

OBJECTIVES:
To compare efficacy and tolerability of drug classes and combinations for chronic heart failure (HF) based on evidence from randomised controlled trials (RCTs) to populate an economic model with updated estimates. METHODS: A systematic literature review (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) identified 54 RCTs of angiotensin converting enzyme inhibitors (ACEI), beta-blockers (BB), angiotensin II receptor blockers (ARB), and aldosterone antagonists (AA). Efficacy and tolerability results of individual studies were combined by network meta-analyses. RESULTS: Numbers of regimens which could be compared varied, depending on the outcome considered. For all-cause deaths and left-ventricular ejection fraction (LVEF), 10 regimens could be included (ACEI; BB; ARB; BBϩACEI; ARBϩACEI; AAϩACEI; BBϩACE or ARB; BBϩACEIϩARB; BBϩACEI or ARBϩAA; ACEI or ARB); for other outcomes, up to five of these could not be included. All-cause deaths varied from 4 per 100 person-years (95% Credible Interval: 1-12) for the combination of AA, BB and ACEI or ARB to 14 per 100 person-years (9-22) for ACEI. Hospitalisation rates varied from 74 hospital stays per 100 patient-years (53-104) with the combination of BB and ACEI to 106 hospital stays per 100 patient-years (63-181) with BB. Increase in LVEF was the highest for the combination of ACEI, ARB and BB (8.44%; 4.24-12.96), followed by the combination of AA, ACEI or ARB, and BB (7.11%; 4.57-9.71). Withdrawal rates (all cause) were higher for the combinations of ACEI and ARB (70 per 100 patient-years; 41-128) and lower for the combination of ACEI, ARB and BB (0; 0-25). Withdrawals rates (due to adverse events) showed similar results. CONCLUSIONS: Network meta-analyses allow the estimation and comparisons of efficacy and tolerability of HF drug classes and combinations. The ranking of treatments from best to worst varied across outcomes, but an overall conclusion was that combinations were the most efficacious without being necessarily the least tolerable. 
PCV13 ARE STATINS EFFECTIVE TO PREVENT FIRST NON-FATAL MYOCARDIAL INFARCTION IN REAL LIFE IN A LOW-RISK COUNTRY? A POPULATION-BASED CASE-REFERENT STUDY USING THE PGRX INFORMATION SYSTEM
OBJECTIVES:
To assess the impact of real life statin utilization on the risk of first non-fatal myocardial infarction (MI) METHODS: Case-control methodology using the pharmacoepidemiological information system 'PGRx'. Data on comorbidities, risk factors and medications were obtained from medical records and patient telephone interviews. General practices (nϭ371) and cardiology centres (nϭ60) across France were employed in the study. Cases were patients with the first MI Ͻϭ1 month before the date of recruitment (nϭ2238). Controls were patients seen by a general practitioner (GP) with no restriction as to the reasons of consultation (nϭ2238), matched to MI cases on gender, age, frequency of visits to a doctor, date of recruitment and personal history of non-cardiovascular chronic disease. Statin exposure was defined as any utilisation in the two-year prior to date of MI in cases or recruitment date in controls. Adjusted odds ratios (OR) of the risk of first MI was estimated by multiple conditional logistic regression models. 
CONCLUSIONS:
In this first major population-based observational study we reproduced the results observed in recent meta-analyses accounting for real life compliance and population variability. The results could be of interest and applicable to other industrialised countries as the observed risk reduction was constant across MI risk levels. 
PCV14 COLESEVELAM FOR THE TREATMENT OF HYPERLIPIDEMIA: A RETROSPECTIVE 'REAL-WORLD' ANALYSIS FROM AN INTEGRATED HEALTH SYSTEM
OBJECTIVES:
To examine effectiveness of Colesevelam in reducing low-density lipoprotein cholesterol (LDL-C) among patients with hyperlipidemia (HL) in the real-world setting. METHODS: In this retrospective study, patients with HL were identified through electronic health records, who were Ն18 years old, and had an initial order for colesevelam between Jan 2004 and Dec 2011, an LDL-C value within 3 months of the initial order date (baseline), and Ն12 months of LDL follow-up and continuous colesevelam treatment. Outcome measures were LDL-C and the percent of patients at the appropriate LDL-C goal based on NCEP ATP III guidelines. Generalized estimating equation models were used to assess differences in LDL-C outcome measures between baseline and 12-months follow-up, adjusting for covariates including statin and other medication use. A p-value Ͻ0.05 was considered statistically significant. Missing data were imputed by linear interpolation. Sensitivity analysis with and without imputation was performed. RESULTS: A total of 468 patients met the predefined inclusion criteria and had a mean age of 63 years old. Of these patients, 48.7% were females and 73.3% had prior statin use. Mean change in LDL-C from baseline at 12 months was -11.4 mg/dL (pϽ0.0001), a relative decrease of 9.6%. The percent of patients at LDL-C goal at baseline was 42.3%, which increased to 56.2% (pϽ0.0001) at 12 months. CONCLUSIONS: Long-term, continuous colesevelam treatment was associated with a significant reduction in LDL-C and an increase in the percent of patients achieving LDL-C goal from baseline. This is the first 'real-world' analysis demonstrating the benefits of colesevelam among patients with HL in a community-based integrated health system. The LDL-C lowering results parallel findings from pivotal clinical trials.
PCV15 BIAS-CORRECTED INDIRECT COMPARISON META-ANALYSIS OF NEW ORAL ANTICOAGULANT IN ATRIAL FIBRILLATION
Cucherat M Faculté de Médecine Laennec, Lyon, France
OBJECTIVES: Meta-epidemiological studies have shown that open-label trials were potentially biased and, in average, overestimate treatment effect magnitude by about 14% compared to double-blind trials. In network meta-analysis where the two types of trials are present, this bias could influence indirect comparisons and favor the less rigorous trials. The objective was to estimate the relative efficacy of apixaban compared to other new anticoagulants (NOAC) in stroke and systemic embolism prevention in atrial fibrillation (AF) using indirect comparison metaanalysis and taking into account the bias of open-label trial such RELY (dabigatran).
METHODS:
We performed a systematic literature review to identify all RCTs evaluating NOAC in AF. Adjusted indirect comparisons and bias correction were conducted using methods derived from those described by Bucher et al. and Welton et al., respectively The data about the use of ACE inhibitors were taken from the Agency for Drugs and Medical Devices of the Serbia. RESULTS: During both analyzed years significant part of consumption of ACE inhibitors was taken by more expensive drugs in Serbia, as fosinopril, cilazapril and quinapril, though they have not been used in Norway at all during that period. During 2009 year, fosinopril as a very expensive drug took second, and during 2010 it took third place on the list of the total utilization of monocomponent ACE inhibitors in Serbia. If the consumption of fosinopril in Serbia was reduced to a minimum as in Norway, and if the patients were offered enalapril instead, the savings in Serbia in 2009 would have been around 7.800.000,00 € only from this product. CONCLUSIONS: In Serbia in 2009 and 2010 year, ACE inhibitors and their fixed combination with diuretics are the most frequently used drugs within the group of drugs which is used for cardiovascular diseases treatment. The amount and structure of the utilized ACE inhibitors in Serbia is different in a lot of ways from the amount and structure of the utilized ACE A364 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5
